About this event
As the NHS financial year draws to an end we bring together our esteemed panel of NHS commentators with specific expertise in rare diseases to help you interpret the strategic and tactical changes within the NHS and its likely impact on industry.
This timely 60-minute masterclass for LSAA members will help YOU enhance patient outcomes during 2024 and beyond.
Henry is the founder of Oxygen - a strategic healthcare public affairs company based in the new diplomatic precinct of Nine Elms in London.
Andrew is a highly experienced Global Market Access expert, leading pragmatic, solution-focused consultancy services at Initiate, a best-in-class consultancy with exceptional experience in the rare disease sector.
Steve heads up IQVIAs Market Access function and brings extensive Industry experience, having worked across a number of pharmaceutical companies, most recently at Merck where he led on Market Access across their broad portfolio.
In 2022, after gaining five years of valuable experience in the gene therapy sector with a focus on reimbursement and commercialization at Bluebird Bio in Europe, Nicola established NJ Redfern Ltd. Her expertise in rare diseases, oncology, and hematology has been dedicated to pricing, reimbursement, service delivery, and shaping the external landscape.
David, born in the Black Country in 1967 and now living near London, is the founder of Sagio consultancy, specializing in delivering insightful "eureka" moments to clients through extensive experience in marketing and strategic consulting.
Ian co-founded the Life Science Access Academy with Nigel Robbins to bring together all the best ideas in people development from more than 20 innovative specialist consultancies.
LSAA is a truly Global Membership Community for all staff from across the Life Science sector including: commercial, clinical and financial sales teams, medics and support teams.
Share this event